Antiepileptic Drugs Market
Antiepileptic Drugs Market Forecasts to 2030 - Global Analysis By Types of Seizures (Partial-onset seizures, Generalized seizures and Other Types of Seizures), Route of Administration (Intravenous, Oral and Other Route of Administrations), Drug Generation, Distribution Channel and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $18.5 BN |
|
Projected Year Value (2030) |
US $28.7 BN |
|
CAGR (2023 - 2030) |
6.5% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Antiepileptic Drugs Market is accounted for $18.5 billion in 2023 and is expected to reach $28.7 billion by 2030 growing at a CAGR of 6.5% during the forecast period. Epilepsy is a neurological disorder characterized by recurrent and unpredictable seizures, which are caused by abnormal electrical activity in the brain. Antiepileptic drugs work by modulating the electrical activity in the brain, preventing or reducing abnormal impulses that lead to seizures. AEDs stabilize cell membranes, enhance inhibitory neurotransmitters like GABA, block sodium channels, reduce glutamate excitability, or modulate calcium channels.
According to World Health Organization (WHO) on February 09, 2023, 5 million people are diagnosed globally with epilepsy every year. Epilepsy is estimated to affect 49 persons out of every 100,000 in high-income countries every year.
Market Dynamics:
Driver:
Advancements in drug development
Continuous research and development efforts have led to the discovery of new formulations, novel mechanisms of action, and improved drug delivery systems, revolutionizing the landscape of antiepileptic treatments. The introduction of next-generation antiepileptic drugs has aimed to address limitations associated with traditional therapies, such as adverse side effects and incomplete seizure control. Additionally, advanced formulations, including extended-release versions, offer improved dosing regimens, enhancing patient adherence and overall treatment efficacy. These advancements in drug development propel market demand.
Restraint:
Side effects
Common side effects include dizziness, fatigue, cognitive impairment, and mood alterations, which can significantly impact patients' quality of life. The challenge lies in balancing the therapeutic benefits of seizure control with the tolerability of these side effects. Moreover, the occurrence of adverse reactions may lead to patient dissatisfaction, non-compliance, or discontinuation of treatment, impeding the effectiveness of antiepileptic therapy. These side effects pose a significant restraint, hampering market expansion.
Opportunity:
Rising prevalence of epilepsy
Epilepsy is a neurological disorder characterized by recurrent seizures, and it affects a substantial number of individuals worldwide. The rising prevalence of epilepsy can be attributed to several factors. Firstly, improved diagnostic techniques and increased awareness of epilepsy have contributed to a higher detection rate. As medical knowledge and technological advancements have improved, healthcare professionals are better equipped to diagnose and classify epilepsy accurately. Additionally, awareness campaigns and educational programs have helped spread knowledge about epilepsy symptoms and the importance of early diagnosis, leading to more individuals seeking medical attention.
Threat:
Social stigma
Despite advancements in understanding the neurological condition, societal misconceptions persist, contributing to reluctance among individuals to seek appropriate treatment. The stigma surrounding epilepsy may lead to under diagnosis and under treatment, as some individuals may avoid disclosing their condition or seeking medical help due to fear of social judgment or discrimination. This unwillingness to discuss epilepsy in public can worsen misinformation, prevent patients from receiving the necessary and efficient treatment that antiepileptic medications provide, and impede patient education. These factors impede market demand.
Covid-19 Impact
The COVID-19 pandemic has significantly impacted the Antiepileptic Drugs (AEDs) market. Pandemic has underscored the importance of ensuring a resilient healthcare system. Telehealth solutions and remote patient monitoring have gained prominence, providing alternative avenues for epilepsy management. Additionally, the focus on research and development to address neurological complications of COVID-19 has indirectly contributed to advancements in understanding epilepsy and related disorders. Moreover, supply chain disruptions and economic uncertainties have impacted the production and distribution of AEDs, affecting market dynamics.
The third generation segment is expected to be the largest during the forecast period
The third generation segment is estimated to hold the largest share. These drugs, such as lacosamide, eslicarbazepine, and perampanel, exhibit enhanced specificity and efficacy in managing epileptic seizures. Third-generation AEDs often target novel molecular pathways, providing a broader spectrum of action and greater selectivity in modulating neuronal activity. One key feature of third-generation AEDs is their focus on minimizing side effects and drug interactions, thus improving overall tolerability. This is particularly important in enhancing patient adherence to treatment regimens.
The Oral segment is expected to have the highest CAGR during the forecast period
The Oral segment is anticipated to have lucrative growth during the forecast period. Oral administration involves the ingestion of antiepileptic drugs in the form of tablets, capsules, or liquids, allowing for convenient and efficient drug absorption through the gastrointestinal tract. The oral route provides flexibility in drug formulation, enabling the development of extended-release formulations that release the medication gradually over time. This feature helps maintain consistent drug levels in the bloodstream, optimizing therapeutic efficacy and minimizing fluctuations that could trigger seizures.
Region with largest share:
North America commanded the largest market share during the extrapolated period owing to robust healthcare infrastructure, advanced medical research, and a high prevalence of epilepsy-related disorders. The region's well-established pharmaceutical industry, coupled with substantial investments in research and development, fosters innovation in antiepileptic treatments. Moreover, the presence of key market players and the adoption of cutting-edge technologies contribute to the region's leadership in advancing treatment options.
Region with highest CAGR:
Asia Pacific is expected to witness profitable growth over the projection period, due to increasing awareness, growing healthcare infrastructure, and a rising incidence of epilepsy-related disorders. A shift towards better diagnostics and increased patient education further fuels the demand for antiepileptic medications in this region. Additionally, with a diverse demographic and a substantial patient base, the region represents a significant growth opportunity for pharmaceutical companies engaged in the development and distribution of antiepileptic drugs.
Key players in the market
Some of the key players in the Antiepileptic Drugs Market include Eisai Co., Ltd., Novartis AG, Merck KGaA, Teva Pharmaceutical Industries Ltd., AstraZeneca, Abbott, Sanofi, Pfizer Inc., GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd., Johnson & Johnson Service, Inc., Zogenix, Alkem Labs, SK Biopharmaceuticals and Sun Pharmaceutical Industries Ltd.
Key Developments:
In June 2023, Pfizer announced a strategic collaboration with Truveta to deliver new safety insights on a continuous basis, using verifiable real-world data at scale.
In January 2021, Novartis announced collaboration with Alnylam to leverage Alnylam’s proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.
Types of Seizures Covered:
• Partial-onset seizures
• Generalized seizures
• Other Types of Seizures
Route of Administrations Covered:
• Intravenous
• Oral
• Other Route of Administrations
Drug Generations Covered:
• First Generation
• Second Generation
• Third Generation
Distribution Channels Covered:
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Other Distribution Channels
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Antiepileptic Drugs Market, By Types of Seizures
5.1 Introduction
5.2 Partial-onset seizures
5.3 Generalized seizures
5.4 Other Types of Seizures
6 Global Antiepileptic Drugs Market, By Route of Administration
6.1 Introduction
6.2 Intravenous
6.3 Oral
6.4 Other Route of Administrations
7 Global Antiepileptic Drugs Market, By Drug Generation
7.1 Introduction
7.2 First Generation
7.2.1 Carbamazepine
7.2.2 Phenytoin
7.2.3 Valproate
7.2.4 Oxycarbazepine
7.2.5 Ethosuximide
7.2.6 Topiramate
7.2.7 Primidone
7.2.8 Phenobarbital
7.3 Second Generation
7.3.1 Pregabalin
7.3.2 Lamotrigine
7.3.3 Levetiracetam
7.3.4 Rufinamide
7.3.5 Eslicarbazepine acetate
7.3.6 Lacosamide
7.3.7 Perampanel
7.3.8 Zonisamide
7.4 Third Generation
8 Global Antiepileptic Drugs Market, By Distribution Channel
8.1 Introduction
8.2 Retail Pharmacies
8.3 Hospital Pharmacies
8.4 Online Pharmacies
8.5 Other Distribution Channels
9 Global Antiepileptic Drugs Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Eisai Co., Ltd.
11.2 Novartis AG
11.3 Merck KGaA
11.4 Teva Pharmaceutical Industries Ltd.
11.5 AstraZeneca
11.6 Abbott
11.7 Sanofi
11.8 Pfizer Inc.
11.9 GlaxoSmithKline plc
11.10 Dr. Reddy's Laboratories Ltd.
11.11 Johnson & Johnson Service, Inc.
11.12 Zogenix
11.13 Alkem Labs
11.14 SK Biopharmaceuticals
11.15 Sun Pharmaceutical Industries Ltd.
List of Tables
1 Global Antiepileptic Drugs Market Outlook, By Region (2021-2030) ($MN)
2 Global Antiepileptic Drugs Market Outlook, By Types of Seizures (2021-2030) ($MN)
3 Global Antiepileptic Drugs Market Outlook, By Partial-onset seizures (2021-2030) ($MN)
4 Global Antiepileptic Drugs Market Outlook, By Generalized seizures (2021-2030) ($MN)
5 Global Antiepileptic Drugs Market Outlook, By Other Types of Seizures (2021-2030) ($MN)
6 Global Antiepileptic Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
7 Global Antiepileptic Drugs Market Outlook, By Intravenous (2021-2030) ($MN)
8 Global Antiepileptic Drugs Market Outlook, By Oral (2021-2030) ($MN)
9 Global Antiepileptic Drugs Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
10 Global Antiepileptic Drugs Market Outlook, By Drug Generation (2021-2030) ($MN)
11 Global Antiepileptic Drugs Market Outlook, By First Generation (2021-2030) ($MN)
12 Global Antiepileptic Drugs Market Outlook, By Carbamazepine (2021-2030) ($MN)
13 Global Antiepileptic Drugs Market Outlook, By Phenytoin (2021-2030) ($MN)
14 Global Antiepileptic Drugs Market Outlook, By Valproate (2021-2030) ($MN)
15 Global Antiepileptic Drugs Market Outlook, By Oxycarbazepine (2021-2030) ($MN)
16 Global Antiepileptic Drugs Market Outlook, By Ethosuximide (2021-2030) ($MN)
17 Global Antiepileptic Drugs Market Outlook, By Topiramate (2021-2030) ($MN)
18 Global Antiepileptic Drugs Market Outlook, By Primidone (2021-2030) ($MN)
19 Global Antiepileptic Drugs Market Outlook, By Phenobarbital (2021-2030) ($MN)
20 Global Antiepileptic Drugs Market Outlook, By Second Generation (2021-2030) ($MN)
21 Global Antiepileptic Drugs Market Outlook, By Pregabalin (2021-2030) ($MN)
22 Global Antiepileptic Drugs Market Outlook, By Lamotrigine (2021-2030) ($MN)
23 Global Antiepileptic Drugs Market Outlook, By Levetiracetam (2021-2030) ($MN)
24 Global Antiepileptic Drugs Market Outlook, By Rufinamide (2021-2030) ($MN)
25 Global Antiepileptic Drugs Market Outlook, By Eslicarbazepine acetate (2021-2030) ($MN)
26 Global Antiepileptic Drugs Market Outlook, By Lacosamide (2021-2030) ($MN)
27 Global Antiepileptic Drugs Market Outlook, By Perampanel (2021-2030) ($MN)
28 Global Antiepileptic Drugs Market Outlook, By Zonisamide (2021-2030) ($MN)
29 Global Antiepileptic Drugs Market Outlook, By Third Generation (2021-2030) ($MN)
30 Global Antiepileptic Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
31 Global Antiepileptic Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
32 Global Antiepileptic Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
33 Global Antiepileptic Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
34 Global Antiepileptic Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
